Oramed Pharmaceuticals Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDOramed Pharmaceuticals Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 88), indicating clear outperformance against the broad market. Earnings growth of 41% provides fundamental context to the price action. Momentum will need to be maintained above the 50-day moving average to sustain this leadership phase.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $3.88 | +0.86% | ABOVE |
| 50 SMA | $3.61 | +8.28% | ABOVE |
| 100 SMA | $3.44 | +13.67% | ABOVE |
| 150 SMA | $3.12 | +25.38% | ABOVE |
| 200 SMA | $2.90 | +34.87% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is ORMP in an uptrend right now?
ORMP has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, ORMP is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is ORMP overbought or oversold?
ORMP's RSI (14) is 57. The stock is in neutral territory, neither overbought nor oversold.
Is ORMP outperforming the market?
ORMP has a Relative Strength (RS) Rating of 88 out of 99. Yes, ORMP is a market leader, outperforming 88% of all stocks over the past 12 months.
Where is ORMP in its 52-week range?
ORMP is trading at $3.91, which is 93% of its 52-week high ($4.22) and 86% above its 52-week low ($1.98).
How volatile is ORMP?
ORMP has a Beta of 1.21 and 52-week volatility of 48%. It's more volatile than the S&P 500 - expect bigger swings.